Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
about
Sympathetic nervous system and chronic bladder pain: a new tune for an old songModulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamideCystolithiasis in a Syrian hamster: a different outcomeLong-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.Visceral and somatic hypersensitivity in TNBS-induced colitis in ratsNMDA Receptors and Colitis: Basic Science and Clinical Implications.The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.Synaptic connections between endomorphin 2-immunoreactive terminals and μ-opioid receptor-expressing neurons in the sacral parasympathetic nucleus of the rat.Local activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents.Intrathecal cannabinoid-1 receptor agonist prevents referred hyperalgesia in acute acrolein-induced cystitis in rats.Neurotrophins in the lower urinary tract: becoming of ageThe effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathyEvaluation of fatty acid amides in the carrageenan-induced paw edema model.Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation.Short-term effect of acute and repeated urinary bladder inflammation on thigmotactic behaviour in the laboratory rat.Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats.Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.Potential Future Pharmacological Treatment of Bladder Dysfunction.Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors.Effect of palmitoylethanolamide on inflammatory and neuropathic pain in ratsInvolvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats.CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons.Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems.Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation.Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
P2860
Q26773584-CE104199-83EE-46F8-B652-AC57C0F5EB65Q28248981-33177668-707E-4542-B9C6-8398B5A9B337Q30376301-99C2709A-4F76-4006-B221-C2AD10517132Q31028236-185670F2-080D-4156-8078-70D665FD5DEDQ31122398-9E209CC2-6577-47C1-B507-C4922F1A1A65Q33596153-9054553D-B2BF-4B5F-A64C-90FDFA6EB416Q33930017-04A6F530-B3D3-47E7-80D1-48758FB7DF0AQ34464535-9110A09E-B1CE-4A92-9C28-ECE336CD6E34Q34720477-E8D2E397-B83A-48FB-A047-5455631CDD5EQ35047740-C4C55A7C-3A67-4F51-8D6E-91FCA9F13F21Q35656543-7A924A82-F132-4643-AC52-77B10E3E842CQ35687029-EE0BA508-1C62-4BB2-AB10-81C696428196Q36094329-DA20399E-9C15-469D-8FEE-B38B02999308Q36384547-1B6539EF-9150-44C2-A565-EE4A2E255631Q36421472-6034E55E-5BFB-4B2C-B98D-57792CA568FDQ36851391-F7879AC6-0128-41CE-9575-12BA40F1D044Q36992061-C8BE01FB-D432-43D8-A1DE-044EFCE8024EQ38157791-895D0706-F4E8-4B8B-8552-EAF3A3375AFCQ38166997-42C258E5-6CFF-4D7E-A22A-79BC3479BF38Q38779624-44CFB57E-3894-4E0C-9B80-75C8A1616511Q40774621-6F4BE934-3D96-4511-B612-8B6B59C1A061Q42379739-0A6C6C85-76DA-4A71-B1CB-0D406308E62AQ42501114-29B9D17B-F983-456C-B6BD-DE49593DD2F4Q42566809-7FB79A17-395E-48CA-94FC-E6E36C260C2CQ44304365-B58AAC16-47F6-4B72-8407-C4A38550EE7AQ45022904-97353416-E281-4038-9EC4-8FB7CABF02F5Q55053411-3A63FF95-471A-470B-A021-54AFD5E3644A
P2860
Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Administration of endocannabin ...... mation of the urinary bladder.
@ast
Administration of endocannabin ...... mation of the urinary bladder.
@en
type
label
Administration of endocannabin ...... mation of the urinary bladder.
@ast
Administration of endocannabin ...... mation of the urinary bladder.
@en
prefLabel
Administration of endocannabin ...... mation of the urinary bladder.
@ast
Administration of endocannabin ...... mation of the urinary bladder.
@en
P1433
P1476
Administration of endocannabin ...... mation of the urinary bladder.
@en
P2093
W P Farquhar-Smith
P304
507-13; discussion 6A
P356
10.1097/00000542-200103000-00023
P407
P577
2001-03-01T00:00:00Z